Metagenomi Therapeutics, Inc. (MGX) Form 10-Q — Aug 10, 2026
Metagenomi Therapeutics reported a Q2 2026 net loss of $27.5 million, or $0.73 per share, widening from $19.9 million a year earlier, as collaboration revenue turned negative at $(0.3) million. The negative quarter reflects a $2.6 million cumulative catch-up reduction tied to an April 2026 modification of the Ionis Pharmaceuticals agreement, which also discontinued the exploratory research program and its cost reimbursements. The company ended the quarter with $120.7 million in cash, cash equivalents and marketable securities against a $361.4 million accumulated deficit, and used $40.7 million of operating cash in the first half of 2026.
Key figures
- Revenue
- Q2 2026: -$0.257M (negative due to $2.6M Ionis catch-up reduction); 1H 2026: $0.991M vs $12.640M in 1H 2025
- Total Assets
- 173701000
- Cash Position
- 39028000
- Shares Outstanding
- 37777105
- Cash runway
- at least 12 months
- Ga expense q2 2026
- 6004000
- Rd expense q2 2026
- 22512000
- Acuitas license fee
- 3000000
- Stockholders equity
- 112567000
- Ionis upfront payment
- 80000000
- Total cash securities
- 120700000
- Atm capacity remaining
- 75000000
- Federal nol carryforwards
- 175300000
- Shelf registration capacity
- 250000000
- Q2 2025 collaboration revenue
- 8513000
- Six month collaboration revenue
- 991000
- Vittoria investment carrying value
- 2200000
- Remaining performance obligations ionis
- 12700000
Price after filing
Close on the filing date to close N calendar days later (from $1.23). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.